Ultragenyx Pharmaceutical Inc. (RARE) Institutional Ownership & Insider Trading

310 institutions reported holding Ultragenyx Pharmaceutical Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 29 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RAREUltragenyx Pharmaceutical Inc.Follow RARE — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.5B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

310 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +9.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	310	107	+9.1%	113	52	96	40
Mar 26	294	98	+5.9%	120	52	79	43
Dec 25	281	94	-7.0%	106	40	87	58
Sep 25	294	100	+6.9%	124	40	84	50
Jun 25	307	94	+4.5%	108	47	102	36
Mar 25	296	89	+2.5%	115	27	93	37
Dec 24	308	88	+0.3%	106	32	99	37
Sep 24	297	86	-1.9%	101	50	87	25

Ultragenyx Pharmaceutical Inc. — questions

Who owns Ultragenyx Pharmaceutical Inc. stock?: 310 institutions reported Ultragenyx Pharmaceutical Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (10.8%), RTW INVESTMENTS, LP (7.9%), VANGUARD PORTFOLIO MANAGEMENT LLC (6.9%).
Are Ultragenyx Pharmaceutical Inc. insiders buying or selling?: 29 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Ultragenyx Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.